Supplementation with DHA and the psychological functioning of young adults

D. Benton1*, R. T. Donohoe1, D. E. Clayton1,2 and S. J. Long1

1Department of Psychology, University of Wales Swansea, Swansea SA2 8PP, UK
2Glion Institute of Higher Education, Les Roches-Grayère University of Applied Sciences, Rue de l’Ondine 20, CH-1630 Bulle, Switzerland

(Submitted 5 October 2011 – Final revision received 27 January 2012 – Accepted 27 January 2012 – First published online 13 April 2012)

Abstract

The grey matter of the brain contains high levels of the essential nutrient DHA. Although the role of DHA in the developing brain and in dementia has attracted attention, its influence on the brain of the healthy adult has been little considered. A total of 285 young adult females took 400 mg of DHA, in a double-blind, placebo-controlled trial, for 50 d. After 50 d, recently acquired information was more likely to be forgotten by those who had consumed DHA. No significant differences in mood, reaction times, vigilance or visual acuity were found.

Key words: DHA: Memory: Mood: Vigilance

About 50–60% of the dry weight of the brain is lipid, of which 35% consists of PUFA(1). In fact, the nature of the dietary intake of PUFA has neurophysiological consequences, as the nature of the diet influences the composition of cell membranes and thus the functioning of the brain(2). A review suggested that the consumption of n-3 PUFA might beneficially affect neuronal composition, neurotransmission and cognitive functioning. Neurotransmission is influenced by two mechanisms: by changing membrane fluidity and by increasing the release of neurotransmitters(3). Epidemiological and developmental research has suggested the role of n-3 PUFA in the regulation of monoamine-mediated systems, cognition and affect: for example, n-3 PUFA have been implicated in depressive disorders, suicide, aggression and impulsivity(4,5).

Although low levels of DHA have been associated with neurodegenerative diseases including dementia(6–8), the literature is limited and inconsistent. A prospective study(9) measured the plasma fatty acid levels in older adults, but over a 3-year period they were not associated with changes in cognition. A cross-sectional longitudinal study(10) examined the relationship between fish/n-3 consumption and cognitive performance and after a 6-year follow-up found no association. However, a 13-year prospective study of 3294 adults found that self-reported cognitive difficulties were less frequent in those with a higher consumption of n-3 PUFA, even after adjustment for depressive symptoms. The authors concluded that cognitive complaints were less frequent among the elderly who had a high intake of n-3 PUFA 13 years earlier(11). Although some observational studies have found that a better n-3 PUFA status was beneficial, it is important that a 2-year double-blind, randomised, controlled trial did not(12). Healthy older adults (aged 70–79 years) took, each day, 200 mg EPA plus 500 mg DHA, or olive oil, but there was no significant difference in cognitive performance. The authors concluded that the relatively short length of the intervention period might have masked the potential beneficial effect of fish oil.

When considering the rate of cognitive decline, the time-scale of supplementation may be critical. Benton(13) noted that age-related changes in brain structure begin to occur up to 60 years before they become overtly apparent as cognitive problems. The time-scale of studies of older adults may have in many instances failed to reflect the slow speed of the processes they were trying to reduce. Yet it is known that there is a rapid turnover of fatty acids in the brain, such that over a relatively short period the structure of cell membranes will reflect the diet of the recent past. In rats, Rapoport(14,15) used radio-labelled PUFA to establish the rate at which they were incorporated into brain phospholipids and found that 3–5% of arachidonic acid (AA) and 2–8% of DHA are lost each day by metabolic mechanisms, to be potentially replaced by dietary sources. Such a rate of turnover gave half-lives of 1–2 weeks for the exchange of AA and DHA between the
plasma and brain. In human subjects, it was determined by positron emission tomography that the human brain consumes 17·8 mg/d of AA and 4·6 mg/d of DHA; values that did not change significantly with age\(^{16}\). Thus, dietary supplementation may increase the levels of plasma PUFA and in this way influence the nature of their turnover in the brain and the resulting PUFA profile. It should, however, be remembered that there are bodily compensations for a diet low in PUFA, so that there is up-regulation of liver enzymes associated with the metabolism of AA and DHA from their precursors\(^{17}\).

Although there is a report in young adults that supplementation with DHA for 12 weeks was associated with increased cerebral blood flow\(^{17}\), cognition was not influenced and in fact there has been little study on the influence of PUFA supplements in this age group. Fontani et al\(^{18,19}\) reported that n-3 supplements increased aspects of mood although never was a significant difference with the placebo reported. Antypa et al\(^{20}\) gave n-3 PUFA supplements for a month and measured performance on a battery of tests and found few effects, although the n-3 PUFA group made fewer risk-averse decisions.

In summary, a dietary increase of n-3 PUFA may influence behaviour by changing the structure of cell membranes and enhancing neurotransmission\(^{20}\). To date, much of the research has considered cognitive decline; however, as it takes place over many years, it would not be expected to be susceptible to a relatively short-term intervention. A possibility that has been little considered is that there might be in young adults a beneficial response to a relatively short-term intervention; one that is long enough to reflect the rate of PUFA turnover. That is, rather than looking to prevent cognitive decline, functioning may be facilitated in the short-term by providing an optimal intake for the healthy brain. The present study therefore gave fatty acid supplements to young, healthy adults and monitored cognition and mood.

Methods

For practical reasons, dictated by the ability to test a given number of subjects, the study took place in two phases. Initially, a group of 150 was recruited and subsequently a second group of 150 subjects took part 3 months later. The data presented are for these two parts combined. As it was possible that changes in diet associated with the time of year might have influenced the findings, initially the statistics allowed for any differences between the two halves of the study to be distinguished. As differences did not occur, they are not further mentioned. All subjects took the battery of cognitive tests and then were randomly allocated to either the DHA or placebo condition using a double-blind procedure. Following baseline testing, four capsules were taken each day. The cognitive battery was taken for a second time after 25 d and for a third time after 50 d. The tests were taken in the following order: mood, word list immediate recall, reaction times, vigilance, word list delayed recall. In addition, with the first half of the subjects, visual acuity was measured after vigilance. With the second half of the subjects, visual acuity was not measured but the recall of capital cities was the first test of the battery, but only during the third testing session (after 50 d). Trying to recall missing capitals on this occasion was the final test of the sequence. The study was conducted according to the guidelines of the Declaration of Helsinki and all procedures were approved by the ethics committee of the Psychology Department of Swansea University. All subjects gave written informed consent.

Subjects

A total of 305 adult females, mean age 21·8 years and all university students were recruited when they responded to a poster. They gave written informed consent and were paid £30 for taking part. The procedure was approved by the local ethics committee. No subject was taking fish oil, or similar fatty acid supplement, and all reported that they were in good health. In total, 285 finished the trial although none reported withdrawing because of side effects.

Supplements

Placebos and active capsules were produced by Martek Biosciences Corporation. The active DHASCO\(^\circ\) capsules contained deodorised and bleached oil derived from the microalgae Cryptothecodinium cohnii, which was added to high-oleic sunflower oil so that 40\% of the resulting mixture was DHA. Antioxidants, tocopherols (0·025\%) and ascorbyl palmitate (0·025\%), and the flavouring ethyl vanillin with a sweet, creamy, vanilla taste and odour, were added. The fatty acid profile was as follows: 10 : 0 (0·5\%); 12 : 0 (3·8\%); 14 : 0 (12·1\%); 16 : 0 (7·8\%); 18 : 0 (1·0\%); 18 : 1 (31·2\%); 18 : 2 (1·5\%); 20 : 0 (0·3\%); 22 : 0 (DHA) 40·1\%. Thus, there was no detectable EPA or other long-chain PUFA. With this as composition, four 250 mg capsules a day offered 400 mg of DHA. The placebos were identical in size, colour and smell to the active capsules and contained maize/soya oil to which ethyl vanillin was added. The fatty acid profile was as follows: 16 : 0 (11·0\%); 18 : 0 (3·0\%); 18 : 1 (23·3\%); 18 : 2 (56·7\%); 18 : 5 (4·1\%); 20 : 0 (0·4\%); 20 : 1 (0·3\%); 22 : 0 (0·2\%).

Cognitive tests

Recall of word list

For this test, three matched lists of thirty nouns were created, all of five letters and one syllable in length. Nouns were selected on the basis of high frequency (AA: >100/million words; A: 50–100/million words), high imagery and high concreteness\(^{21}\). They were presented at the rate of one word/s. Immediately after presentation, the subjects wrote down as many words as they could recall in 2 min (immediate memory task). Approximately 25 min later, following the other tests, the subjects again tried to recall the words (delayed memory task). The same word list was presented to all subjects at a particular testing session.

Recall of capitals

This test was only given to the second group of subjects. As the test could not be meaningfully repeated, it was administered...
only during the final testing session, that is after taking the capsules for 50 d. In a pilot study, the subjects were asked to report the capitals of various countries and, if they were unable to recall them at that moment, to rate whether they thought they knew them. From these responses, a list of thirty countries was created, which consisted of countries where it was common to report that they had a feeling that they knew the capital although they were unable to recall the same.

The list of thirty countries was given to the subjects who, where possible, mentioned the capital. Where they did not know the answer, they rated their ‘feeling of knowing’ on a six-point scale (1 = very strong feeling of knowing to 6 = definitely do not know).

Having carried out the rest of the test battery, the list of countries was given a second time and any capitals subsequently remembered were reported. The responses obtained on the second occasion were expressed as a portion of the number of answers previously unanswered.

**Reaction times**

The reaction time procedure was based on that of Jensen (22). On a panel, eight lamps were arranged in a semicircle 5·5 inches from a central button (the home key). The index finger was placed on the home key. Following a warning tone, one of the eight lamps flashed and the subject pressed the button in front of the illuminated lamp. The decision time is the time taken to lift the finger from the home key. Simple and choice decision times for each of two, four and eight lamps were measured over twenty trials.

**Rapid information processing task**

A computer generated a series of digits at the rate of 100 digits/min for 5 min. Subjects pressed the space bar when they detected target sequences of three consecutive odd or three consecutive even digits. In this manner, eight of these sequences were presented every minute. The numbers of correct and incorrect responses were analysed.

**Visual acuity**

Visual acuity was measured using Snellen charts and was only given to the first group of subjects. To increase sensitivity, the charts were read from a distance of 5 m rather than the recommended 3 m. Thus two charts were presented, one of numbers and one of letters. Both charts were presented to the right, and then both were presented to the left eye. The measure analysed was the total number of letters and numbers that were not reported correctly.

**Mood assessment**

Visual analogue scales (100 mm lines) were used to assess how the subjects had felt ‘during the past week’: were they energetic–tired, clearheaded–confused, composed–anxious, confident–unsure, elated–depressed and agreeable–hostile? These dimensions were derived from the factor analysis that was carried out when the Profile of Mood States questionnaire (23) was developed.

**Side effects**

After taking the capsules, the subjects were asked if they had experienced any side effects and also to indicate whether they believed they were taking the active capsules, placebo or could not tell.

**Statistical analysis**

Most analyses of the influence of DHA used a three-way ANOVA; DHA/placebo × first/second group of subjects × time (tested for the first, second or third time), with the last as a repeated-measures factor. Significant interactions were explored by the calculation of simple main effects. Whether the results came from the first or second half of the subjects did not influence the findings and these details are therefore not reported. The effects of the capsules on the recall of capitals, and ‘feeling of knowing’, were examined using t tests.

**Results**

**Word list recall**

When recall of the word lists was considered, the interaction capsule × time × immediate/delayed recall (F(2, 566) = 4·41, P<0·01) reached significance. Fig. 1 illustrates the interaction that reflects differences between immediate and delayed recall; that is the amount forgotten. Those taking DHA tended to forget more at the end of the study. Post hoc tests found that those taking DHA rather than the placebo forget more after 50 d (P<0·01).
To consider whether this was a genuine effect, rather than simply due to statistical chance, the sample was reanalysed in two halves reflecting the first half of the subjects that had been run as one group and the second half that was tested some months later. In both cases, there was a trend for forgetting to be worse at the end of the study in those who took DHA, albeit it did not reach statistical significance. The number forgotten at the end of the study for the first group of subjects was placebo 2.6 (SE 0.21) and DHA 3.2 (SE 0.28), $P < 0.07$, figures that compared well with the second half of the study that produced values for the placebo of 2.6 (SE 0.27) and DHA 3.2 (SE 0.29), $P < 0.09$. There was evidence of a consistent pattern that when these data were merged, it produced an overall effect of 2.6 (SE 0.19) words being forgotten with the placebo and 3.2 (SE 0.19) with DHA ($P < 0.01$).

Recall of capitals

Table 1 reports that those taking the DHA did not differ significantly in terms of the number of capitals initially recalled, the feeling that they knew the correct answer but were unable to recall it, or the number of additional capitals recalled when the task was undertaken for a second time.

Mood

The interaction capsule $\times$ time failed to reach statistical significance in the case of agreeable ($F(2,566) = 0.47$, NS), clearheaded ($F(2,566) = 0.02$, NS), composed ($F(2,566) = 0.38$, NS), confident ($F(2,566) = 0.62$, NS), elated ($F(2,566) = 0.19$, NS) and energetic ($F(2,566) = 1.57$, NS). Mean values are presented in Table 1.

### Table 1. The influence of DHA supplementation on mood and various measures of cognitive functioning*

(Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th></th>
<th>25 d</th>
<th></th>
<th>50 d</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean SE</td>
<td>Mean SE</td>
<td>Mean SE</td>
<td></td>
<td>Mean SE</td>
<td></td>
</tr>
<tr>
<td>Recall of capital cities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial recall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>14.0 5.8</td>
<td>15.0 5.4</td>
<td>15.0 5.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>12.5 5.2</td>
<td>13.0 5.4</td>
<td>13.0 5.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feeling of knowing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>5.0 0.56</td>
<td>5.0 0.56</td>
<td>5.0 0.56</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>5.0 0.52</td>
<td>5.0 0.52</td>
<td>5.0 0.52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Second recall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>1.4 0.15</td>
<td>1.4 0.15</td>
<td>1.4 0.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>1.4 0.15</td>
<td>1.4 0.15</td>
<td>1.4 0.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decision times</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>353.7 4.4</td>
<td>353.2 3.5</td>
<td>353.2 3.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>346.9 4.4</td>
<td>342.4 3.6</td>
<td>342.4 3.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vigilance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Correct</td>
<td>4.2 0.11</td>
<td>4.6 0.12</td>
<td>4.6 0.12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>4.3 0.12</td>
<td>4.7 0.12</td>
<td>4.7 0.12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incorrect</td>
<td>2.6 0.89</td>
<td>2.1 0.24</td>
<td>2.1 0.24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>4.0 0.89</td>
<td>2.7 0.25</td>
<td>2.7 0.25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual acuity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>20.5 1.8</td>
<td>19.4 1.8</td>
<td>19.4 1.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>20.2 1.8</td>
<td>19.2 1.8</td>
<td>19.2 1.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Composed–anxious</td>
<td>21.2 0.8</td>
<td>22.7 0.8</td>
<td>22.7 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>20.7 0.8</td>
<td>21.7 0.8</td>
<td>21.7 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>23.0 0.8</td>
<td>23.0 0.8</td>
<td>23.0 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agreeable–hostile</td>
<td>26.2 0.7</td>
<td>26.0 0.8</td>
<td>26.0 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>25.5 0.7</td>
<td>25.7 0.8</td>
<td>25.7 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>26.3 0.7</td>
<td>26.3 0.7</td>
<td>26.3 0.7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elated–depressed</td>
<td>22.7 0.9</td>
<td>23.1 0.9</td>
<td>23.1 0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>21.5 0.9</td>
<td>22.3 0.9</td>
<td>22.3 0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>24.1 0.8</td>
<td>24.1 0.8</td>
<td>24.1 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confident–unsure</td>
<td>20.4 0.8</td>
<td>21.4 0.8</td>
<td>21.4 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>19.5 0.8</td>
<td>20.1 0.8</td>
<td>20.1 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>21.9 0.8</td>
<td>21.9 0.8</td>
<td>21.9 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energetic–tired</td>
<td>19.0 0.9</td>
<td>18.6 0.9</td>
<td>18.6 0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>18.0 0.9</td>
<td>19.6 0.9</td>
<td>19.6 0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>19.7 0.9</td>
<td>19.7 0.9</td>
<td>19.7 0.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clearheaded–confused</td>
<td>22.1 0.8</td>
<td>22.6 0.8</td>
<td>22.6 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>21.2 0.8</td>
<td>22.4 0.8</td>
<td>22.4 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA</td>
<td>23.5 0.8</td>
<td>23.5 0.8</td>
<td>23.5 0.8</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In no instance was there a significant difference between those taking the placebo and DHA.
**Visual acuity**

The capsules did not influence visual acuity (capsule \( \times \) time – \( F(2,286) = 0.11, \text{NS} \)).

**Reaction times**

When the median decision times were examined, both the capsule \( \times \) number of lamps \( \times \) time (\( R(6,1692) = 0.45, \text{NS} \)) and capsule \( \times \) day (\( F(2,564) = 0.47, \text{NS} \)) interactions were non-significant (Table 1).

**Vigilance**

Some subjects with this task used the strategy of continuously pressing the bar so that by chance correct responses registered. Therefore, any subject who had more than twenty errors in a minute was removed from the analysis so that data are presented for 135 taking the placebo and 126 taking DHA. When the number of sequences correctly identified was examined, the capsule \( \times \) minutes of the session \( \times \) time interaction failed to reach statistical significance (\( F(8,2056) = 0.17, \text{NS} \)) and similarly the capsule \( \times \) time interaction was non-significant (\( F(2,514) = 0.47, \text{NS} \)).

When the number of incorrect responses was examined, neither the capsule \( \times \) minutes of the session \( \times \) time interaction (\( F(8,2056) = 0.90, \text{NS} \)) nor the capsule \( \times \) time interaction (\( F(2,514) = 0.52, \text{NS} \)) reached statistical significance.

**Side effects**

When asked after 50 d whether they had experienced any side effects, 92% of those taking the placebo and 95% of those taking the DHA, said no. Analysis using \( \chi^2 \) indicated that the responses did not differ depending on which type of capsule had been consumed. In the minority who reported side effects, there was no systematic pattern. Physical and psychological symptoms were equally likely to be reported and when reported they were as likely to be positive as negative. Virtually no symptom was mentioned more than once, but typical examples included increased or decreased pre-menstrual symptoms, feeling less hungry, having more spots or poor fingernails, having improved memory and needing less sleep. When asked to guess which treatment they had received, 60% of those taking the placebo said that they did not know, 8% said DHA and 32% said placebo. Of those taking DHA, 65% said that they did not know, 19% said DHA and 16% said placebo: responses that were not statistically different.

**Discussion**

The present study produced little evidence that DHA supplementation influenced either cognition or mood. In fact, the only significant finding was that DHA increased forgetting, an unexpected finding (Fig. 1). That there was a trend for more to be forgotten in both halves of the study supported the view that it was a genuine rather than a chance result, but naturally such a finding requires replication. The failure to find any difference in the ability to recall the names of capitals (Table 1) suggested that there was no problem in retrieving information from long-term memory stores; and so the finding must reflect some other aspect of the memory process. There is, however, in principle, no reason why \( n-3 \) fatty acid supplementation may not have both positive and negative influences.

The failure to find that mood was influenced is perhaps more surprising (Table 1). Although methodological problems with the studies have been noted, Fontani et al.\(^{(18,19)}\) reported that PUFA supplementation improved mood. Benton\(^{(24)}\) considered studies that had assessed aggression and in well-controlled trials had given DHA supplements. In this connection, eight studies were subjected to a meta-analysis that established a significant beneficial effect of consuming DHA. As an example, Hamazaki et al.\(^{(25)}\) reported that 1.5–1.8 g of DHA/d for 3 months decreased aggression towards others, in times of mental stress. There is a parallel between these findings and those of Iribarren et al.\(^{(26)}\). In a study of risk factors associated with heart disease in 3581 young adults, the consumption of any fish rich in \( n-3 \) fatty acids, rather than no fish consumption, was associated with a lower risk of hostility. In fact, there have been suggestions that a tendency to consume a diet low in \( n-3 \) pre-disposes to being aggressive. When monkeys ate a low-fat diet (30% rather than 43% of energy from fat), they displayed more aggression\(^{(27)}\).

However, when for a month young adults ate a diet with either 41 or 25% of energy as fat, ratings of anger–hostility were greater when less fat was consumed\(^{(28)}\). However, for 3 months, Rogers et al.\(^{(29)}\) gave EPA/DHA supplements to individuals who were mildly to moderately depressed and found no effect on measures of depression or on a range of cognitive tests. They included their findings in a meta-analysis and found that \( n-3 \) PUFA supplements offered negligible benefits in terms of depressed mood. Interestingly, the effect of the DHA supplement approached statistical significance with a measure of impulsivity\(^{(29)}\) (\( P<0.07 \)), suggesting that although mood in general may not be influenced, the possibility that impulsivity and aggression are influenced should be further considered. Antypa et al.\(^{(30)}\), however, did not find an influence on impulsivity although \( n-3 \) PUFA supplementation increased risky decisions.

One possible explanation for the present study’s failure to find an influence on mood is that the dose of DHA may be critical. The doses used in the eight studies reviewed by Benton\(^{(24)}\) varied but tended to offer at least 1.5 g DHA and in addition at least 100 mg EPA, usually more. It is an obvious suggestion that the dose in the present study was too low or that in addition EPA should have been provided. An 85 g portion of salmon offers about 1.2 g of \( n-3 \) fatty acids, which puts the dose in perspective, although the recommendation to eat fish twice a week is unlikely to provide the recommended intake of 1000–2000 mg/d.

Nevertheless, the failure to find a general effect on mood agrees with work published since the present study was completed. Jackson et al.\(^{(30)}\) gave one of three types of capsules (450 mg DHA + 90 mg EPA; 200 mg DHA + 300 mg EPA; placebo) in healthy young adults aged 18–35 years. A battery of cognitive tasks and measures of mood were completed before...
and after 12 weeks of supplementation. The authors described the effects of both active treatments as minimal. The only significant finding was that the high-EPA capsules reduced mental fatigue when under high cognitive demand. They concluded that they had not produced solid evidence of any psychological influence. Thus, it does not seem that the giving of EPA was critical.

Jackson et al.\(^{(30)}\) speculated that their negative findings might have reflected the existing diet not providing a sufficiently low level of \(n\)-3 fatty acids to allow a benefit from supplementation to be observed. An animal study suggested that there might be a threshold of \(n\)-3 PUFA intake below which there is a positive response to supplementation. Jensen et al.\(^{(31)}\) fed rats diets that differed in their PUFA content. Only when brain levels of \(n\)-3 PUFA fell to 22\% was the ability to perform in a water maze compromised. Similarly, a South African study found a response to fish oil in under-nourished but not well-nourished children\(^{(32)}\).

Jackson et al.\(^{(30)}\) considered their finding that ratings of mental fatigue were reduced in those consuming \(n\)-3 PUFA, results similar to those of Antypa et al.\(^{(20)}\) who also found less fatigue in individuals taking fatty acids. They speculated that the intake of EPA could modulate the metabolism of pro-inflammatory AA-derived eicosanoids\(^{(33)}\) and that a high level of pro-inflammatory cytokines is associated with tiredness. If so, a reduced AA:EPA ratio might be beneficial in times of cognitive demand. The present findings that DHA supplementation did not decrease fatigue is consistent with this analysis as the present supplement did not contain EPA, although until the administration of DHA and EPA gets to be compared, this remains only an interesting hypothesis.

The present findings, taken together with other recent negative reports, suggest that dietary supplementation with \(n\)-3 PUFA in healthy, impairment-free populations is unlikely to result in cognitive enhancement. It should, however, be noted that the lack of a measure of baseline fatty acid status or subsequent changes is a weakness of the design that make the generality of the findings uncertain. However, the negative findings are consistent with the few similar studies that have to date been reported in adults\(^{(20,29,30)}\) and children\(^{(34–37)}\), although in children there is an isolated partially positive report\(^{(32)}\). It is therefore surprising that there is a widespread belief that the consumption of \(n\)-3 fatty acids enhances the functioning of the brain. A website selling \(n\)-3 supplements claimed thus: ‘Recent studies have shown that \(n\)-3 DHA and EPA can improve learning, problem-solving skills, focus, memory and overall brain function’ and recommended the consumption of their product for those from 2 to 102 years of age. A list of the ten best foods and supplements for brain health stated that: ‘A lack of \(n\)-3 has been shown to diminish intellectual performance’. It is important that individuals are not given false hopes, as although to date there have been few studies on this topic, the findings are consistently negative.

**Acknowledgements**

The funding supplied by Novartis Nutrition Research A.G., and the supply of the DHA capsules and placebos by Martek Biosciences Corporation, are gratefully acknowledged. No author has any financial interest in matters related to the present study or any other conflict of interest. D. B. and D. E. C. designed the study; R. T. D. collected the data; R. T. D., D. B. and S. J. L. analysed the data and wrote the manuscript.

**References**

19. Jackson PA, Reay JL, Scholey AB, et al. (2012) Docosahexaenoic acid-rich fish oil modulates the cerebral hemodynamic...


